A clinical trial evaluating a treatment regimen consisting of the antiviral remdesivir plus the immunomodulator interferon beta-1a in patients with COVID-19 is now underway. The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), will involve more than 1,000 hospitalized adults with COVID-19. The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health, and will take place at up to 100 sites both in the U.S. and abroad. As a premium courier, Yourway ships drug products around the world, ensuring that all high-value supplies reach their destination as scheduled.